Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
BACKGROUND Statin therapy prior to percutaneous coronary intervention ( PCI ) is associated with reduced mortality and periprocedural myocardial injury after PCI . We studied whether single high dose statin loading is beneficial on the outcome of patients with acute coronary syndrome ( ACS ) underwent PCI . METHODS Consecutive 445 patients with ACS who underwent PCI were r and omly assigned to either the group of no statin treatment before PCI ( Control group : n=220 , 63+/-11 years , male 62 % ) or the group of 40 mg rosuvastatin loading before PCI ( Rosuvastatin group : n=225 , 64+/-10 years , male 60 % ) . Incidence of periprocedural myocardial injury was assessed by analysis of creatinine kinase-MB ( CK-MB ) and cardiac troponin T before PCI , at 6 h and the next morning after PCI . RESULT There were no significant differences in clinical characteristics between the two groups . After PCI , incidence of periprocedural myocardial injury was higher in control than in rosuvastatin group ( 11.4 % versus 5.8 % , p=0.035 ) . Mean preprocedural CK-MB and high sensitivity C-reactive protein were similar between the two groups , whereas after PCI , peak values of both markers were elevated significantly higher in control than in rosuvastatin group . Multivariate analysis revealed that no prior use of statin ( OR=2.2 ; 95 % CI=1.1 - 4.6 ; p=0.029 ) , procedural complication ( OR=3.1 ; 95 % CI=1.4 - 6.9 ; p=0.007 ) and multi-vessel disease ( OR=2.6 ; 95 % CI=1.0 - 6.6 ; p=0.039 ) were the independent predictors for periprocedural myocardial infa rct ion . CONCLUSION Single high dose of rosuvastatin prior to PCI reduces periprocedural myocardial injury in patients with ACS
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .